Regeneron Pharmaceuticals (NASDAQ: REGN) climbed 13.33% on October 30, 2026, closing at $927.89, up $109.12 from the previous close of $818.77. The stock’s after-hours price stood at $926.00, down $1.89, or 0.20%.
During the regular session, shares traded between $839.08 and $935.35, opening at $869.43. Trading volume reached approximately 2.85 million shares, substantially above the average volume of 733,951. The company’s intraday market capitalization was approximately $95.99 billion.
The five-day chart showed a gain of approximately 15.26%, with the share price moving toward its 52-week high of $935.35. The broader 52-week trading range was $591.52 to $935.35.
Company Overview
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for patients worldwide. Headquartered in Tarrytown, New York, the company was incorporated in 1988.
Its portfolio addresses a broad range of medical conditions, including eye diseases, allergic and inflammatory disorders, cardiovascular and metabolic conditions, neurological and infectious diseases, and cancer.
Among its marketed treatments are EYLEA and EYLEA HD for retinal diseases, Dupixent for certain inflammatory conditions, Libtayo for cancer, and Praluent for patients with heterozygous familial hypercholesterolemia. The company also markets Kevzara for rheumatoid arthritis and develops treatments across several additional therapeutic areas.
Regeneron maintains strategic collaborations with pharmaceutical and biotechnology companies, including Bayer, Alnylam Pharmaceuticals, Intellia Therapeutics, Hansoh Pharmaceutical Group, Tessera Therapeutics, Telix Pharmaceuticals, CytomX Therapeutics, and Sanofi.
The company reported approximately 15,410 full-time employees.
Financial and Valuation Snapshot
Regeneron had an intraday market capitalization of approximately $95.99 billion. Its trailing price-to-earnings ratio was 20.51, while earnings per share stood at $45.24.
The one-year analyst target estimate was $929.00, slightly above the October 30 closing price of $927.89. The stock’s 52-week range placed its latest close near the upper end of its trading history.
The company also reported a forward dividend of $3.76, representing a yield of approximately 0.41%. Its next listed ex-dividend date was November 20, 2026.
Upcoming Events and Corporate Developments
Regeneron’s Q3 2026 earnings call was available for replay, with options to review the transcript and listen to the call. The market data listed January 28, 2027, as the estimated next earnings date.
The company’s extensive development portfolio and collaborations remain important elements of its business profile, spanning ophthalmology, immunology, oncology, cardiovascular medicine, and emerging therapeutic technologies.
Market Outlook
Regeneron recorded a substantial one-day share-price increase, accompanied by trading volume well above its reported average. Its closing price approached the 52-week high, while the five-day chart reflected continued upward momentum.
The company’s valuation, diversified therapeutic portfolio, and strategic partnerships provide important reference points for assessing its market position. However, the supplied trading data does not identify the specific catalyst behind the October 30 rally.
Investors will be watching subsequent earnings disclosures, clinical development progress, and commercial performance to evaluate whether the recent share-price strength can be sustained.
